human breast cancer cell lines mda mb 231 triple negative  (ATCC)

Journal: Advanced Science

Article Title: ZBTB21 Is a Dual Suppressor of Pyroptosis and MHC‐I Antigen Presentation That Promotes Tumor Immune Evasion

doi: 10.1002/advs.202519836

Figure Lengend Snippet: ZBTB21 loss enhances tumor immunogenicity and response to immunotherapy through MHC‐I upregulation. (A) Association between ZBTB21 expression and HLA/B/C across human cancers (TCGA dataset). (B) Transcriptomic analysis of ZBTB21 ‐KO versus Control 4T1 cells. GSEA plots corresponding to each Hallmark pathway, displaying the normalized enrichment score (NES), nominal p value (Nominal P), and FDR (FDR q). A Hallmark pathway was considered significantly enriched if it met the following criteria: |NES| > 1, nominal p value < 0.05, and FDR q value < 0.25. (C) Representative staining profiles (left) and H‐2Kb SIINFEKL MFI (right) in Control+OVA and ZBTB21 ‐KO+OVA cells ( n = 5). (D) Cytotoxicity analysis of splenic OT‐I T cells cocultured with OVA‐expressing B16F10 tumor cells versus ZBTB21 ‐KO B16F10 tumor cells ( n = 5). (E) Representative staining profiles (left) and IFN‐γ detection results (right) of T cells following co‐culture with ZBTB21 ‐KO MDA‐MB‐231 cells or parental MDA‐MB‐231 cells ( n = 4). (F,G) Tumor growth curves ( n = 5) and overall survival curves ( n = 7) of tumor‐bearing mice inoculated with Control, ZBTB21 ‐ B2m ‐KO, or ZBTB21 ‐KO tumor cells. (H,I) Tumor growth curves for Control, ZBTB21 ‐ B2m ‐KO, or ZBTB21 ‐KO tumor tumor‐bearing mice treated with PD1 or CTLA‐4 antibodies ( n = 5). (J) Tumor growth ( n = 5) and overall survival ( n = 6) curves for Control, ZBTB21 ‐ B2m ‐KO, or ZBTB21 ‐KO tumor‐bearing mice treated with OVA‐encoding mRNA‐LNP vaccine or empty‐vector mRNA‐LNP as control. (K) Representative staining profiles (left) of CD8 and percentages (right) of CD8 + T cells among CD45 + cells in Control, ZBTB21 ‐ B2m ‐KO, or ZBTB21 ‐KO tumors ( n = 5). (L) Representative staining profiles (left) and IFN‐γ MFI (right) in Control, ZBTB21 ‐ B2m ‐KO, or ZBTB21 ‐KO tumors ( n = 5). Data are presented as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, no significance. Data were analyzed by two‐way ANOVA, Log‐rank (Mantel‐Cox) test or unpaired two‐tailed Student's t ‐test.

Article Snippet: Mouse triple‐negative breast cancer cell line 4T1 (Cat# CRL‐2539), mouse melanoma cell line B16F10 (Cat# CRL‐6475), mouse hepatocellular carcinoma cell line Hepa1‐6 (Cat# CRL‐1830), human triple‐negative breast cancer cell line MDA‐MB‐231 (Cat# CRM‐HTB‐26), human malignant melanoma cell line A375 (Cat# CRL‐1619), human non‐small cell lung cancer cell line H1299 (Cat# CRL‐5803), and human embryonic kidney 293T (Cat# CRL‐3216) cells were obtained from the American Type Culture Collection.

Techniques: Immunopeptidomics, Expressing, Control, Staining, Co-Culture Assay, Plasmid Preparation, Two Tailed Test

Journal: bioRxiv

Article Title: A comprehensive analysis of humanized mouse models for the study of cancer immunotherapies

doi: 10.1101/2025.09.04.674233

Figure Lengend Snippet: A. Experimental design. 5 or 10×10 6 CD3 + T cell-containing Hu-PBMCs were injected two weeks before tumor graft (red lines) or after tumor graft was detectable (green lines); 1 week for tumor cell lines, up to 8 weeks for PDXs. As reference, tumor growth was measured in mice non injected with PBMCs (black lines). B. Individual tumor growth kinetics of LCF29 (NSCLC PDX), BC138 (TNBC PDX), HCC827 (NSCLC cell line) and MDA-MB231 (TNBC cell line). C. Tumor growth kinetics represented as mean ± SEM of individual curves shown in (B). D. GvHD development was followed by weight loss, represented by percentage (%) of initial weight. C, D. Data are represented as mean ± SEM of n=3-9 mice per group. E. Blood was recovered to measure Hu-CD45 + cells 30 days after Hu-PBMCs injection for LCF29, 22 days for BC138, 27 days for HCC827, and 20 days for MDA-MB231. F, G. NSG mice were not grafted with tumor (black, n=79) or grafted with NSCLC lung tumor cell line (HCC827, red, n=17), NSCLC PDX (orange, n=81), breast tumor cell line (MDA-MB231, dark green, n=52) or breast PDX (light green, n=31). Then mice were injected with 5×10 6 to 7.5×10 6 CD3 + T cell-containing Hu-PBMCs. Mice were evaluated for Hu-CD45 + staining in blood. F. Proportion of reconstituted mice. Mice were considered reconstituted when more than 2% of Hu-CD45 + were detected at two different time points. Numbers above bars indicates number of reconstituted mice/total PBMCs injected mice. G. Frequency (%) of Hu-CD45 + cells in reconstituted tumor-bearing mice at the maximal percentage of Hu-CD45 + cells detected in F (between day 30 and day 40 after tumor graft) with the mean shown for each group. Data is from a pool of several experiments.

Article Snippet: Human triple negative breast cancer MDA-MB231 cell line, NSCLC cancer HCC827 cell line (ATCC) and HT-29 colorectal cell line (ATCC) were grown in RPMI medium (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (Biosera), glutamine and penicillin-streptomycin (Life Technologies).

Techniques: Injection, Staining